{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:26:35Z","timestamp":1790717195413,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100014717","name":"National Outstanding Youth Science Fund Project of National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81803907"],"award-info":[{"award-number":["81803907"]}],"id":[{"id":"10.13039\/100014717","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012401","name":"Beijing Science and Technology Plan Project","doi-asserted-by":"crossref","award":["Z171100001717021"],"award-info":[{"award-number":["Z171100001717021"]}],"id":[{"id":"10.13039\/501100012401","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s10620-020-06141-5","type":"journal-article","created":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T21:04:17Z","timestamp":1582578257000},"page":"19-28","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"66","author":[{"given":"Yuan","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chune","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiongqiong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fushun","family":"Kou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,24]]},"reference":[{"key":"6141_CR1","first-page":"1","volume":"30","author":"E Savarino","year":"2017","unstructured":"Savarino E, De BN, De CC, et al. The natural history of gastro-esophageal reflux disease: a comprehensive review. Dis Esophagus.. 2017;30:1\u20139.","journal-title":"Dis Esophagus."},{"key":"6141_CR2","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1136\/gutjnl-2012-304269","volume":"63","author":"HB El-Serag","year":"2014","unstructured":"El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-esophageal reflux disease: a systematic review. Gut.. 2014;63:871\u2013880.","journal-title":"Gut."},{"key":"6141_CR3","doi-asserted-by":"publisher","first-page":"5762","DOI":"10.3748\/wjg.v21.i19.5762","volume":"21","author":"C Triantos","year":"2015","unstructured":"Triantos C, Koukias N, Karamanolis G, et al. Changes in the esophageal mucosa of patients with non erosive reflux disease: how far have we gone? World J. Gastroenterol.. 2015;21:5762\u20135767.","journal-title":"World J. Gastroenterol."},{"key":"6141_CR4","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s10620-016-4409-6","volume":"62","author":"R Yadlapati","year":"2017","unstructured":"Yadlapati R, Dakhoul L, Pandolfino JE, et al. The quality of care for gastroesophageal reflux disease. Dig. Dis. Sci.. 2017;62:569\u2013576. https:\/\/doi.org\/10.1007\/s10620-016-4409-6","journal-title":"Dig. Dis. Sci."},{"key":"6141_CR5","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00535-016-1227-8","volume":"51","author":"K Iwakiri","year":"2016","unstructured":"Iwakiri K, Kinoshita Y, Habu Y, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol.. 2016;51:751\u2013767.","journal-title":"J Gastroenterol."},{"key":"6141_CR6","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/ajg.2012.444","volume":"108","author":"PO Katz","year":"2013","unstructured":"Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol.. 2013;108:308\u2013328.","journal-title":"Am J Gastroenterol."},{"key":"6141_CR7","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","volume":"152","author":"D Freedberg","year":"2017","unstructured":"Freedberg D, Kim LS, Yang Y-X. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology.. 2017;152:706\u2013715.","journal-title":"Gastroenterology."},{"key":"6141_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5009\/gnl15502","volume":"11","author":"DS Strand","year":"2017","unstructured":"Strand DS, Kim D, Peura D. 25 years of proton pump inhibitors: a comprehensive review. Gut Liver.. 2017;11:27\u201337.","journal-title":"Gut Liver."},{"key":"6141_CR9","doi-asserted-by":"publisher","first-page":"1756283X1774577","DOI":"10.1177\/1756283X17745776","volume":"11","author":"K Sugano","year":"2018","unstructured":"Sugano K. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Ther Adv Gastroenterol.. 2018;11:1756283X17745776.","journal-title":"Ther Adv Gastroenterol."},{"key":"6141_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1124\/jpet.110.170274","volume":"335","author":"Y Hori","year":"2010","unstructured":"Hori Y, Imanishi A, Matsukawa J, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)1H-pyrrol-3-yl]-n-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther.. 2010;335:231\u2013238.","journal-title":"J Pharmacol Exp Ther."},{"key":"6141_CR11","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1124\/jpet.111.179556","volume":"337","author":"Y Hori","year":"2011","unstructured":"Hori Y, Matsukawa J, Takeuchi T, et al. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther.. 2011;337:797\u2013804.","journal-title":"J Pharmacol Exp Ther."},{"key":"6141_CR12","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.bcp.2011.02.009","volume":"81","author":"J Matsukawa","year":"2011","unstructured":"Matsukawa J, Hori Y, Nishida H, et al. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol.. 2011;81:1145\u20131151.","journal-title":"Biochem Pharmacol."},{"key":"6141_CR13","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1124\/jpet.111.185314","volume":"339","author":"JM Shin","year":"2011","unstructured":"Shin JM, Inatomi N, Munson K, et al. Characterization of a novel potassium competitive acid blocker of the gastric H, K-atPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3ylsulfonyl)-1H-pyrrol-3-yl]-n-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther.. 2011;339:412\u2013420.","journal-title":"J Pharmacol Exp Ther."},{"key":"6141_CR14","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1007\/s00535-019-01572-y","volume":"54","author":"H Miwa","year":"2019","unstructured":"Miwa H, Igarashi A, Teng L, et al. Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease. J Gastroenterol.. 2019;54:718\u2013729.","journal-title":"J Gastroenterol."},{"key":"6141_CR15","unstructured":"Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. version 5.1.0.2011. www.handbook.cochrane.org. Retrieved June 4, 2018."},{"key":"6141_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","volume":"151","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Int Med.. 2009;151:65.","journal-title":"Ann Int Med."},{"key":"6141_CR17","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1007\/s10620-019-5464-6","volume":"64","author":"K Sakurai","year":"2019","unstructured":"Sakurai K, Suda H, Fujie S, et al. Correction to: Short-term symptomatic relief in gastroesophageal reflux disease: a comparative study of esomeprazole and vonoprazan. Dig Dis Sci.. 2019;64:1724. https:\/\/doi.org\/10.1007\/s10620-019-5464-6.","journal-title":"Dig Dis Sci."},{"issue":"2","key":"6141_CR18","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/apt.15062","volume":"49","author":"T Oshima","year":"2019","unstructured":"Oshima T, Arai E, Taki M, et al. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis. Aliment Pharmacol Ther.. 2019;49(2):140\u2013146.","journal-title":"Aliment Pharmacol Ther."},{"key":"6141_CR19","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1136\/gutjnl-2019-318365","volume":"69","author":"YL Xiao","year":"2019","unstructured":"Xiao YL, Zhang ST, Dai N, et al. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis. Gut.. 2019;69:224\u2013230.","journal-title":"Gut."},{"key":"6141_CR20","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.3748\/wjg.v24.i14.1550","volume":"24","author":"K Ashida","year":"2018","unstructured":"Ashida K, Iwakiri K, Hiramatsu N, et al. Maintenance for healed erosive esophagitis: phase III comparison of vonoprazan with lansoprazole. World J Gastroenterol.. 2018;24:1550\u20131561.","journal-title":"World J Gastroenterol."},{"issue":"2","key":"6141_CR21","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/apt.13461","volume":"43","author":"K Ashida","year":"2016","unstructured":"Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther.. 2016;43(2):240\u2013251.","journal-title":"Aliment Pharmacol Ther."},{"issue":"6","key":"6141_CR22","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/apt.13331","volume":"42","author":"K Ashida","year":"2015","unstructured":"Ashida K, Sakurai Y, Nishimura A, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther.. 2015;42(6):685\u2013695.","journal-title":"Aliment Pharmacol Ther."},{"key":"6141_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.curtheres.2016.12.001","volume":"81\u201382","author":"Y Kinoshita","year":"2016","unstructured":"Kinoshita Y, Sakurai Y, Shiino M, et al. Evaluation of the efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a phase III, randomized, double-blind, placebo-controlled, multicenter study. Curr Ther Res Clin Exp.. 2016;81\u201382:1\u20137.","journal-title":"Curr Ther Res Clin Exp."},{"key":"6141_CR24","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40265-015-0368-z","volume":"75","author":"KP Garnock-Jones","year":"2015","unstructured":"Garnock-Jones KP. Vonoprazan: first global approval. Drugs.. 2015;75:439\u2013443.","journal-title":"Drugs."},{"issue":"4","key":"6141_CR25","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1159\/000475658","volume":"95","author":"M Okuyama","year":"2017","unstructured":"Okuyama M, Nakahara K, Iwakura N, et al. Factors associated with potassium-competitive acid blocker non-response in patients with proton pump inhibitor-refractory gastroesophageal reflux disease. Digestion.. 2017;95(4):281\u2013287.","journal-title":"Digestion."},{"key":"6141_CR26","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s10620-017-4866-6","volume":"63","author":"XX Yang","year":"2018","unstructured":"Yang XX, Li YY, Sun YY, et al. Vonoprazan: a novel and potent alternative in the treatment of acid-related diseases. Dig Dis Sci.. 2018;63:302\u2013311. https:\/\/doi.org\/10.1007\/s10620-017-4866-6","journal-title":"Dig Dis Sci."},{"key":"6141_CR27","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/jgh.14664","volume":"34","author":"H Miyazaki","year":"2019","unstructured":"Miyazaki H, Igarashi A, Takeuchi T, et al. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: a systematic review. J Gastroenterol Hepatol.. 2019;34:1316\u20131328.","journal-title":"J Gastroenterol Hepatol."},{"key":"6141_CR28","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/j.1440-1746.2011.06975.x","volume":"27","author":"T Shimatani","year":"2012","unstructured":"Shimatani T, Sugimoto M, Nishino M, et al. Predicting the efficacy of proton pump inhibitors in patients with non-erosive reflux disease before therapy using dual-channel 24-h esophageal pH monitoring. J Gastroenterol Hepatol.. 2012;27:899\u2013906.","journal-title":"J Gastroenterol Hepatol."},{"key":"6141_CR29","doi-asserted-by":"publisher","first-page":"32126","DOI":"10.1038\/srep32126","volume":"6","author":"LX Chen","year":"2016","unstructured":"Chen LX, Chen YJ, Li B. The efficacy and safety of proton-pump inhibitors in treating patients with non-erosive reflux disease: a network meta-analysis. Sci Rep.. 2016;6:32126.","journal-title":"Sci Rep."},{"issue":"7","key":"6141_CR30","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1007\/s10620-014-3104-8","volume":"59","author":"G Sachs","year":"2014","unstructured":"Sachs G, Shin JM, Munson K, et al. Gastric acid-dependent diseases: a twentieth-century revolution. Dig Dis Sci.. 2014;59(7):1358\u20131369. https:\/\/doi.org\/10.1007\/s10620-014-3104-8","journal-title":"Dig Dis Sci."},{"key":"6141_CR31","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1007\/s10620-017-4830-5","volume":"62","author":"Y-M Kung","year":"2017","unstructured":"Kung Y-M, Hsu W-H, Wu M-C, et al. Recent advances in the pharmacological management of gastroesophageal reflux disease. Dig Dis Sci.. 2017;62:3298\u20133316. https:\/\/doi.org\/10.1007\/s10620-017-4830-5","journal-title":"Dig Dis Sci."},{"key":"6141_CR32","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/10773525.2016.1235675","volume":"22","author":"S-H Jang","year":"2016","unstructured":"Jang S-H, Ryu H-S, Choi S-C, et al. Psychological factors influence the gastroesophageal reflux disease (GERD) and their effect on quality of life among firefighters in South Korea. Int J Occup Environ Health.. 2016;22:315\u2013320.","journal-title":"Int J Occup Environ Health."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06141-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-020-06141-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-020-06141-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T14:31:05Z","timestamp":1695825065000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-020-06141-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,24]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["6141"],"URL":"https:\/\/doi.org\/10.1007\/s10620-020-06141-5","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,24]]},"assertion":[{"value":"18 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}